Latest News about RETA
Recent news which mentions RETA
From Benzinga
From Benzinga
Pharma Stock Shoots Up As FDA Accepts NDA For Neuromuscular Disorder Drug Under Priority Review
May 26, 2022
Tickers
RETA
From Benzinga
From Benzinga
From Benzinga
Earnings Scheduled For May 10, 2022
May 10, 2022
From Benzinga
From Benzinga
50 Biggest Movers From Yesterday
March 29, 2022
From Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
March 28, 2022
From Benzinga
35 Stocks Moving In Monday's Mid-Day Session
March 28, 2022
From Benzinga
From Benzinga
Regulus Moving Closer To Potential $25 Million Milestone Payment For Novel Kidney Disease Treatment Licensed To Sanofi
March 18, 2022
From Benzinga
From Benzinga
Reata Pharmaceuticals's Return on Invested Capital Insights
March 01, 2022
Tickers
RETA
From Benzinga
67 Biggest Movers From Yesterday
March 01, 2022
From Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
February 28, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Monday
February 28, 2022
From Benzinga
Earnings Scheduled For February 28, 2022
February 28, 2022
From Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
From Benzinga
The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision
February 25, 2022
From Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
From Benzinga
Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates
February 01, 2022
From Benzinga
3 Stocks Insiders Are Buying
January 05, 2022
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.